

CITATION REPORT

List of articles citing

Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets

DOI: 10.1111/apt.12728

Alimentary Pharmacology and Therapeutics, 2014, 39, 1033-4

Source: <https://exaly.com/paper-pdf/58906531/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
144	Serotonergic reinforcement of intestinal barrier function is impaired in irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 392-402	6.1	31
143	Disturbance of the gut microbiota in early-life selectively affects visceral pain in adulthood without impacting cognitive or anxiety-related behaviors in male rats. 2014 , 277, 885-901		185
142	Clinical pilot study: efficacy of triple antibiotic therapy in Blastocystis positive irritable bowel syndrome patients. 2014 , 6, 34		10
141	The Potential for use of Probiotics in Pediatric Irritable Bowel Syndrome and Inflammatory Bowel Disease. 2014 , 2, 235-240		1
140	Prebiotics and probiotics in irritable bowel syndrome and inflammatory bowel disease in children. 2015 , 6, 209-17		23
139	Metabolome of human gut microbiome is predictive of host dysbiosis. 2015 , 4, 42		71
138	Symbiotics in irritable bowel syndrome--better than probiotics alone?. 2015 , 18, 485-9		4
137	Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2015 , 57, 129-34	3.1	41
136	The Intestinal Microbiota and Irritable Bowel Syndrome. 2015 , 49 Suppl 1, S56-9		36
135	THE INTESTINAL MICROBIOTA AND THE ROLE OF PROBIOTICS IN IRRITABLE BOWEL SYNDROME: a review. <i>Arquivos De Gastroenterologia</i> , 2015 , 52, 331-8	1.3	13
134	Blastocystis Isolates from Patients with Irritable Bowel Syndrome and from Asymptomatic Carriers Exhibit Similar Parasitological Loads, but Significantly Different Generation Times and Genetic Variability across Multiple Subtypes. 2015 , 10, e0124006		22
133	Therapeutic Modification of the GI Microbiome. 2015 , 21, 124-130		
132	The newest "omics"--metagenomics and metabolomics--enter the battle against the neglected tropical diseases. 2015 , 9, e0003382		32
131	Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome. 2015 , 16, 607-15		12
130	Irritable bowel syndrome: an integrated explanatory model for clinical practice. 2015 , 27, 750-63		19
129	Risk of cancer in patients with irritable bowel syndrome: a nationwide population-based study. 2015 , 25, 924-8		7
128	Therapeutic Effects and Mechanisms of Action of Rifaximin in Gastrointestinal Diseases. 2015 , 90, 1116-24		23

127	Antibiotic-Induced Depletion of Murine Microbiota Induces Mild Inflammation and Changes in Toll-Like Receptor Patterns and Intestinal Motility. 2015 , 70, 835-48		68
126	[Characterization, influence and manipulation of the gastrointestinal microbiota in health and disease]. 2015 , 38, 445-66		3
125	Microbiota regulation of the Mammalian gut-brain axis. 2015 , 91, 1-62		159
124	Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 418-27	6.1	271
123	Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial. 2015 , 27, 705-16		25
122	New and Investigational Agents for Irritable Bowel Syndrome. 2015 , 17, 46		6
121	Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 71-83	6.1	167
120	Long-term Clinical Course of Post-infectious Irritable Bowel Syndrome After Shigellosis: A 10-year Follow-up Study. <i>Journal of Neurogastroenterology and Motility</i> , 2016 , 22, 490-6	4.4	15
119	Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline. 2016 , 36, 300-16		16
118	A proof-of-concept study showing antibiotics to be more effective in irritable bowel syndrome with than without small-intestinal bacterial overgrowth: a randomized, double-blind, placebo-controlled trial. 2016 , 28, 281-9		44
117	Unexpected improvement in core autism spectrum disorder symptoms after long-term treatment with probiotics. 2016 , 4, 2050313X16666231		36
116	Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches. 2017 , 239, 75-113		17
115	Primary Care Evaluation and Management of Gastroenterologic Issues in Women. 2016 , 43, 347-66		2
114	Faecal short-chain fatty acids - a diagnostic biomarker for irritable bowel syndrome?. <i>BMC Gastroenterology</i> , 2016 , 16, 51	3	51
113	Common functional pain syndromes. 2016 , 16, 334-340		9
112	[Irritable bowel syndrome: the next-to-last that is being investigated]. 2016 , 146, 260-2		4
111	The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions. 2016 , 9, 606-25		104
110	Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation. 2016 , 15, 983-91		13

109	Metagenomic analysis of the human microbiome. 2016 , 95-111		1
108	Irritable bowel syndrome: the next-to-last that is being investigated. 2016 , 146, 260-262		
107	Diarrhea-predominant irritable bowel syndrome: Diagnosis, etiology, and new treatment considerations. 2016 , 28, 393-404		23
106	Microbiome, antibiotics and irritable bowel syndrome. 2016 , 120, 91-99		19
105	Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. <i>BMC Gastroenterology</i> , 2016 , 16, 62	3	105
104	Probiotics in functional bowel disorders. 2016 , 30, 89-97		17
103	Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye?. 2016 , 9, 199-212		44
102	Differences of microbiota in small bowel and faeces between irritable bowel syndrome patients and healthy subjects. 2016 , 51, 410-9		49
101	Composition and temporal stability of the gut microbiota in older persons. 2016 , 10, 170-82		216
100	Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: A systematic review and meta-analysis. 2017 , 49, 331-337		131
99	The Gut Microbiome in Irritable Bowel Syndrome and Other Functional Bowel Disorders. 2017 , 46, 91-101		25
98	Validation and application of an ultrahigh-performance liquid chromatographic-Orbitrap mass spectrometric method for the simultaneous detection and quantification of volatile and non-volatile organic acids in human faecal samples. 2017 , 141, 46-51		9
97	The role of fermentable carbohydrates and beverages in the symptomatology of functional gastrointestinal disease. 2017 , 52, 1224-1234		4
96	Lactobacillus casei DG and its postbiotic reduce the inflammatory mucosal response: an ex-vivo organ culture model of post-infectious irritable bowel syndrome. <i>BMC Gastroenterology</i> , 2017 , 17, 53	3	56
95	The effects of administration of the Lactobacillus gasseri strain CP2305 on quality of life, clinical symptoms and changes in gene expression in patients with irritable bowel syndrome. 2017 , 122, 212-224		20
94	GABA-producing Bifidobacterium dentium modulates visceral sensitivity in the intestine. 2017 , 29, e12904		119
93	Gut Microbiota in Health and Probiotics in Functional Bowel Disease. 2017 , 40, 22		
92	Eluxadolone in the treatment of diarrhea-predominant irritable bowel syndrome. 2017 , 11, 2827-2840		7

91	Long-term irritable bowel syndrome symptom control with reintroduction of selected FODMAPs. 2017 , 23, 4632-4643	66
90	New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond. 2017 , 23, 6593-6627	25
89	Migraine in young females with irritable bowel syndrome: still a challenge. 2018 , 14, 21-28	16
88	Treatment of Functional Bowel Disorders With Prebiotics and Probiotics. 2017 , 355-364	
87	A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies. 2018 , 35, 289-310	107
86	Gut dysbiosis and irritable bowel syndrome: The potential role of probiotics. 2018 , 76, 111-120	27
85	Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease. 2018 , 67, 108-119	368
84	Involvement of shared mucosal-associated microbiota in the duodenum and rectum in diarrhea-predominant irritable bowel syndrome. 2018 , 33, 1220-1226	21
83	Perinatal and familial risk factors for irritable bowel syndrome in a Swedish national cohort. 2018 , 53, 559-566	13
82	An overview on the interplay between nutraceuticals and gut microbiota. 2018 , 6, e4465	17
81	Tong-Xie-Yao-Fang Regulates 5-HT Level in Diarrhea Predominant Irritable Bowel Syndrome Through Gut Microbiota Modulation. 2018 , 9, 1110	22
80	Visceral pain: gut microbiota, a new hope?. 2018 , 25, 73	37
79	Effects of Alkaline-Reduced Drinking Water on Irritable Bowel Syndrome with Diarrhea: A Randomized Double-Blind, Placebo-Controlled Pilot Study. 2018 , 2018, 9147914	11
78	Gut-brain axis biochemical signalling from the gastrointestinal tract to the central nervous system: gut dysbiosis and altered brain function. 2018 , 94, 446-452	23
77	Human microbiome restoration and safety. 2018 , 308, 487-497	27
76	Infection of the Small Intestine Induces Chronic Colitis in Genetically Susceptible Hosts. 2018 , 201, 548-559	19
75	Pharmacokinetic drug evaluation of rifaximin for treatment of diarrhea-predominant irritable bowel syndrome. 2018 , 14, 753-760	7
74	Gut Microbiota in Brain Development and Disorders of the CNS: Therapeutic Strategies Involving Dietary Modification, Pro- and Prebiotic Intervention, and Fecal Microbiota Transplantation (FMT) Therapy. 2018 , 517-594	

73	Fecal and Mucosal Microbiota Profiling in Irritable Bowel Syndrome and Inflammatory Bowel Disease. 2019 , 10, 1655	85
72	Value-based Pricing for Rifaximin Increases Access of Patients With Irritable Bowel Syndrome With Diarrhea to Therapy. 2019 , 17, 2687-2695.e11	7
71	Re: A Meta-Analysis of the Clinical Use of Curcumin for Irritable Bowel Syndrome. 2019 , 8,	1
70	The Microbiome and Irritable Bowel Syndrome - A Review on the Pathophysiology, Current Research and Future Therapy. 2019 , 10, 1136	101
69	Relief of irritable bowel syndrome by fecal microbiota transplantation is associated with changes in diversity and composition of the gut microbiota. 2019 , 20, 401-408	37
68	A decrease in iron availability to human gut microbiome reduces the growth of potentially pathogenic gut bacteria; an in vitro colonic fermentation study. 2019 , 67, 20-27	35
67	Identification of an intestinal microbiota signature associated with hospitalized patients with diarrhea. 2019 , 66, 189-202	3
66	Comparative efficacy and safety of probiotics for the treatment of irritable bowel syndrome: a systematic review and network meta-analysis protocol. 2019 , 9, e027376	4
65	Management of Small Intestinal Bacterial Overgrowth in Adult Patients. 2019 , 42, 269-276	2
64	Neonatal Maternal Deprivation Followed by Adult Stress Enhances Adrenergic Signaling to Advance Visceral Hypersensitivity. 2019 , 35, 4-14	10
63	Changes in Fecal Calprotectin After Rifaximin Treatment in Patients With Nonconstipated Irritable Bowel Syndrome. 2019 , 357, 23-28	5
62	Irritable bowel syndrome and the brain-gut connection. 2020 , 27-42	
61	Adult Stress Promotes Purinergic Signaling to Induce Visceral Pain in Rats with Neonatal Maternal Deprivation. 2020 , 36, 1271-1280	3
60	Viral metagenomic analysis of fecal samples reveals an enteric virome signature in irritable bowel syndrome. 2020 , 20, 123	9
59	Efficacy and Safety of Probiotics in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. 2020 , 11, 332	29
58	Human Gut Microbiota and the Influence of Probiotics, Prebiotics, and Micronutrients. 2021 , 271-271	0
57	Fecal microbiota transplantation for COVID-19; a potential emerging treatment strategy. 2021 , 147, 110476	6
56	Artificial Intelligence based personalized diet: A pilot clinical study for IBS.	1

55	Efficacy and safety of biophenol-rich nutraceuticals in adults with inflammatory gastrointestinal diseases or irritable bowel syndrome: A systematic literature review and meta-analysis. 2021 ,		4
54	Therapeutic implications of SARS-CoV-2 dysregulation of the gut-brain-lung axis. 2021 , 27, 4763-4783		3
53	Gut microbiota and brain function and pathophysiology. 2021 , 335-354		
52	Increased Expression of Colonic Mucosal Melatonin in Patients with Irritable Bowel Syndrome Correlated with Gut Dysbiosis. 2020 , 18, 708-720		6
51	Increased Expression of Colonic Mucosal Melatonin in Patients with Irritable Bowel Syndrome Correlated with Gut Dysbiosis.		1
50	Systematic review: ileoanal pouch microbiota in health and disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 466-477	6.1	23
49	Dual epithelial and immune cell function of Dvl1 regulates gut microbiota composition and intestinal homeostasis. 2016 , 1,		8
48	Natural Useful Therapeutic Products from Microbes. 2014 , 1,		8
47	New psychological therapies for irritable bowel syndrome: mindfulness, acceptance and commitment therapy (ACT). 2017 , 109, 648-657		15
46	Effectiveness of probiotics in irritable bowel syndrome: methodological quality of meta-analyses and systematic reviews. 2019 , 6, 115-121		3
45	Altered profiles of fecal metabolites correlate with visceral hypersensitivity and may contribute to symptom severity of diarrhea-predominant irritable bowel syndrome. 2019 , 25, 6416-6429		9
44	The Role of Intestinal Microbiota and Mast Cell in a Rat Model of Visceral Hypersensitivity. <i>Journal of Neurogastroenterology and Motility</i> , 2020 , 26, 529-538	4.4	8
43	Healing Irritable Bowel Syndrome with Diaphragmatic Breathing. <i>Biofeedback</i> , 2017 , 45, 83-87	0.6	1
42	Methane and Constipation-predominant Irritable Bowel Syndrome: Entwining Pillars of Emerging Neurogastroenterology. <i>Cureus</i> , 2019 , 11, e4764	1.2	0
41	Irritable bowel syndrome and small intestinal bacterial overgrowth: Assessment with breath test. <i>Archives of Clinical Gastroenterology</i> , 041-048	0.1	
40	GUT MICROBIOTA, PREBIOTICS, PROBIOTICS, AND SYNBIOTICS IN GASTROINTESTINAL AND LIVER DISEASES: PROCEEDINGS OF A JOINT MEETING OF THE BRAZILIAN SOCIETY OF HEPATOLOGY (SBH), BRAZILIAN NUCLEUS FOR THE STUDY OF HELICOBACTER PYLORI AND MICROBIOTA (NBEHPM), AND BRAZILIAN FEDERATION OF GASTROENTEROLOGY (FBC). <i>Arquivos De Gastroenterologia</i> , 2020 , 53, 381-398	1.3	4
39	Gastroenterology. 2020 , 913-926		
38	Fecal transplantation: clinical realities and prospects in the treatment of metabolic syndrome. <i>Ekspierimentalnaya I Klinicheskaya Gastroenterologiya</i> , 2020 , 183, 102-112	0.4	

37	The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. <i>Annals of Gastroenterology</i> , 2015 , 28, 203-209	2.2	784
36	Fecal Microbiota Transplantation: A Review of Emerging Indications Beyond Relapsing Clostridium difficile Toxin Colitis. <i>Gastroenterology and Hepatology</i> , 2015 , 11, 24-32	0.7	15
35	Fecal Microbiota Transplantation for Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2016 , 12, 374-9	0.7	21
34	Advances in IBS 2016: A Review of Current and Emerging Data. <i>Gastroenterology and Hepatology</i> , 2016 , 12, 1-11	0.7	10
33	Understanding and Managing IBS and CIC in the Primary Care Setting. <i>Gastroenterology and Hepatology</i> , 2018 , 14, 3-15	0.7	1
32	The Gut-Brain Axis: Influence of Microbiota on Mood and Mental Health. <i>Integrative Medicine</i> , 2018 , 17, 28-32	0.4	18
31	Fecal microbiota profiling in irritable bowel syndrome and inflammatory bowel disease patients with irritable bowel syndrome-type symptoms. <i>BMC Gastroenterology</i> , 2021 , 21, 433	3	0
30	Trait Energy and Fatigue May Be Connected to Gut Bacteria among Young Physically Active Adults: An Exploratory Study.. <i>Nutrients</i> , 2022 , 14,	6.7	3
29	A questionnaire-based survey on the etiopathogenesis of chronic constipation during a medical check-up in Japan.. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2022 , 70, 205-211	3.1	0
28	Glutamine Supplementation Enhances the Effects of a Low FODMAP Diet in Irritable Bowel Syndrome Management.. <i>Frontiers in Nutrition</i> , 2021 , 8, 746703	6.2	1
27	Data_Sheet_1.pdf. 2019 ,		
26	Image_1.pdf. 2018 ,		
25	DataSheet_1.docx. 2020 ,		
24	Image_1.jpeg. 2020 ,		
23	Image_10.jpeg. 2020 ,		
22	Image_11.jpeg. 2020 ,		
21	Image_12.jpeg. 2020 ,		
20	Image_2.jpeg. 2020 ,		

19 Image_3.jpeg. **2020**,

18 Image_4.jpeg. **2020**,

17 Image_5.jpeg. **2020**,

16 Image_6.jpeg. **2020**,

15 Image_7.jpeg. **2020**,

14 Image_8.jpeg. **2020**,

13 Image_9.jpeg. **2020**,

12 Abdominal Nausea and Gastrointestinal Discomfort: A Biofeedback Assessment Model to Create a Rationale for Training. *Biofeedback*, **2022**, 50, 24-32 0.6

11 Effectiveness and Safety of Probiotics for Patients with Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials. *Nutrients*, **2022**, 14, 2482 6.7 o

10 Interferon and HPA Axis: Impact on Neuroimmunological Perturbations.

9 Gut-Brain communication: a novel application of probiotics. **2022**, 405-416 o

8 Potential tolerability of ancient grains in non-celiac wheat sensitivity patients: A preliminary evaluation. 9, o

7 Microbiota- Brain-Gut-Axis Relevance to Parkinson's Disease: Potential Therapeutic Effects of Probiotics.. **2022**, 28, o

6 Artificial intelligence-based personalized diet: A pilot clinical study for irritable bowel syndrome. **2022**, 14, 1

5 Drugging the microbiome and bacterial live biotherapeutic consortium production. **2022**, 78, 102801 o

4 Evaluation of the gut microbiota patterns in patients with COVID-19: a protocol for a pilot study. o

3 Probiotics and women health: clinical perspective. **2023**, 14, 1-9 o

2 Phylogenetic analysis of *Prevotella copri* from fecal and mucosal microbiota of IBS and IBD patients. **2023**, 16, 175628482211363 o

- 1 Modulation of the microbiota across different intestinal segments by Rifaximin in PI-IBS mice. **2023**, 23, o